Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01614821 · FLOW

Participant flow

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia · Source last updated 2020-01-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    PCI-32765; ibrutinib PCI-32765: Taken orally, once daily in the morning
    id
    FG000
    title
    Treatment Arm
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    PCI-32765; ibrutinib PCI-32765: Taken orally, once daily in the morning
    id
    FG000
    title
    Treatment Arm
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice